Etomay, Rosenda G.
HRN: 16-24-09 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/03/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/03/2023
12/10/2023
IV
4.5g As LD Then 2.25g
Q8
Infected Diabetic Foot, Right
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes